In changes to take effect from 1 September, PHARMAC is moving to have a preferred brand of recombinant Factor VIII, while also maintaining full funding for the other three currently-funded haemophilia products.
PHARMAC is consulting on moving to the next stage in its hospital medical devices work – market share procurement.
PHARMAC will begin funding for the prostate cancer treatment abiraterone (Zytiga) from 1 May 2015, potentially benefiting up to 1000 men annually.
Estimated savings achieved through PHARMAC’s tender of off-patent medicines have now topped $600 million.
PHARMAC has secured the first national contract in the hospital medical device category for orthopaedic trauma, spine, and cranio-maxillofacial implants.
PHARMAC is in active negotiations with several suppliers as a result of its competitive process for rare disorders medicines.
We’re giving you the opportunity to tell us how we’re doing, what it’s like to work with us and what we can do better in a stakeholder survey.
Four Māori pharmacy students have been awarded Hiwinui Heke pharmacy scholarships – two each from the Auckland and Otago Schools of Pharmacy.
District Health Boards are poised to save more than $100 million over five years as a result of PHARMAC’s expanded role, PHARMAC reports in its Annual Review, released today.
A new agreement for a high cost biologic drug will yield considerable savings for DHBs over the next five years, says PHARMAC.
PHARMAC will change the way it makes funding decisions from late next year.
DHBs are expected to start making further savings in cardiac medical devices, after PHARMAC extended the range of products it already has under national contracts by beginning listing those used in cardiac procedures.
New Zealand hospitals are about to strengthen their defences against multi-resistant bacterial infections with the funding of a new antibiotic.
PHARMAC decisions to fund four new medicines will improve treatment options for over 10,000 people with a wide range of respiratory conditions.
Nearly 12,000 New Zealanders are set to benefit from major agreements that have been approved by PHARMAC.
Funding for newer and more effective multiple sclerosis treatments has been approved by PHARMAC.
The first funded pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease, will become available from 1 October 2013.
Genetic markers will be used to target a new funded oral treatment for hepatitis C patients from 1 September.
Up to 400 patients a year are likely to live longer as a result of PHARMAC funding two new medicines.
New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender.